BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:valproate readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of valproate\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06714357-8583@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:valproate: Phase 2 readout est. (NCT06714357)
DESCRIPTION:valproate\, phase 2.\nStudy: ValproIc Acid to Potentiate Anti-E
 GFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer\
 nEstimated primary completion: 20 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/valproate#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06714357
URL:https://assetmemo.bio/drug/valproate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431595-8583@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:valproate: Phase 2/3 readout est. (NCT05431595)
DESCRIPTION:valproate\, phase 2/3.\nStudy: Managing Agitated Delirium With 
 Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy\nEstima
 ted primary completion: 2 February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/valproate#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05431595
URL:https://assetmemo.bio/drug/valproate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226141-8583@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:valproate: Phase 1/2 readout est. (NCT07226141)
DESCRIPTION:valproate\, phase 1/2.\nStudy: Valproate for the Treatment of R
 esidual Amblyopia\nEstimated primary completion: 30 September 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/valproate#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07226141
URL:https://assetmemo.bio/drug/valproate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07831369-8583@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:valproate: Phase 2 readout est. (NCT07831369)
DESCRIPTION:valproate\, phase 2.\nStudy: VISTA: Valproic Acid\, Irinotecan\
 , and Simvastatin for Recurrent Glioma\nEstimated primary completion: 30 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/valpro
 ate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07831369
URL:https://assetmemo.bio/drug/valproate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02068586-8583@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:valproate: Phase 2 readout est. (NCT02068586)
DESCRIPTION:valproate\, phase 2.\nStudy: Sunitinib Malate or Valproic Acid 
 in Preventing Metastasis in Patients With High-Risk Uveal Melanoma\nEstima
 ted primary completion: 31 December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/valproate#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT02068586
URL:https://assetmemo.bio/drug/valproate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03048084-8583@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:valproate: Phase 4 readout est. (NCT03048084)
DESCRIPTION:valproate\, phase 4.\nStudy: Seizure Treatment in Glioma\nEstim
 ated primary completion: 1 January 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/valproate#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03048084
URL:https://assetmemo.bio/drug/valproate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02265770-8583@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:valproate: Phase 2/3 readout est. (NCT02265770)
DESCRIPTION:valproate\, phase 2/3.\nStudy: An International Clinical Progra
 m for the Diagnosis and Treatment of Children With Ependymoma\nEstimated p
 rimary completion: June 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/valproate#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT02265770
URL:https://assetmemo.bio/drug/valproate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929273-8583@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20280613
DTEND;VALUE=DATE:20280614
SUMMARY:valproate: Phase 3 readout est. (NCT06929273)
DESCRIPTION:valproate\, phase 3.\nStudy: A Study to Assess the Long-term Sa
 fety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (B
 ALSAM-3)\nEstimated primary completion: 13 June 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/valproate#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06929273
URL:https://assetmemo.bio/drug/valproate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05973786-8583@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:valproate: Phase 3 readout est. (NCT05973786)
DESCRIPTION:valproate\, phase 3.\nStudy: The Effect of a Six Week Intensifi
 ed Pharmacological Treatment for Bipolar Depression Compared to Treatment 
 as Usual in Subjects Who Had a First-time Treatment Failure on Their First
 -line Treatment.\nEstimated primary completion: 30 June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/valproate#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05973786
URL:https://assetmemo.bio/drug/valproate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07166393-8583@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:valproate: Phase 2/3 readout est. (NCT07166393)
DESCRIPTION:valproate\, phase 2/3.\nStudy: Valproic AcId for Traumatic BRAi
 n INjury Trial\nEstimated primary completion: May 2031. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/valproate#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07166393
URL:https://assetmemo.bio/drug/valproate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
